Courtesy of

Focus: Cancer therapies
Based: Berkeley Heights, NJ

Genta's long struggle to stay above water ended in August when the developer of cancer drugs revealed a plan to liquidate assets in a Chapter 7 bankruptcy.

The company had held on by a string for years after the FDA shot down an application for approval of its lead cancer drug Genasense, and the company was forced to slash half of its jobs in 2008. Its top experimental therapy then flunked a late-stage study in melanoma in 2011, leaving its stock too deep in penny-stock territory for most people in biotech to even care.

Yet even as Genta rests in peace (we hope) one never knows where the company's assets could surface. Just weeks before revealing the bankruptcy, the outfit touted its agreement with the FDA on a special protocol assessment (SPA) process for a late-stage study of its oral tesetaxel as a first chemotherapy treatment for women with aggressive breast cancer.

For more:
RIP: After long illness, Genta finally opts to liquidate
Allon, Genta programs win FDA fast-track status
Genta tanks on Genasense data
Faced with cash shortage, Genta considers options


Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.